2-(tert-butoxycarbonylamino)-3-methylsulfanylpropanoic acid | 1429914-24-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(tert-butoxycarbonylamino)-3-methylsulfanylpropanoic acid
• 英文别名: N-(tert-butoxycarbonyl)-S-methylcysteine；N-t-butoxycarbonyl-S-methyl-cysteine；Boc-S-methyl-L-cysteine；2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-methylsulfanylpropanoic acid
• CAS: 1429914-24-8
• 化学式: C₉H₁₇NO₄S
• 分子量: 235.304
• InChiKey: WFDQTEFRLDDJAM-UHFFFAOYSA-N

物化性质

• 沸点：
  388.7±37.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(tert-butoxycarbonylamino)-3-methylsulfanylpropanoic acid 在 sodium carbonate 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 10.5h， 生成
  参考文献：
  名称：

  A ribozyme with michaelase activity

  摘要：

  The ability to generate RNA molecules that can catalyze complex organic transformations not only facilitates the reconstruction and plausibility of possible prebiotic reaction pathways but is also crucial for elucidating the potential of the application of RNA catalysts in organic syntheses. Iterative RNA selection previously identified a ribozyme that catalyzes the Michael addition of a cysteine thiol to an alpha,beta-unsaturated amide. This reaction is chemically similar to the rate limiting step of the thymidylate synthase reaction, which is the corresponding reaction of a cysteine thiol to the double-bond of the uracil nucleobase. Here we provide a detailed description of the synthesis of the ribozyme substrates and the substrate oligonucleotides used for its characterization and the investigation of the background reaction. We also describe the further characterization of the ribozyme with respect to substrate specificity. We show that the thiol group of the cysteine nucleophile is essential for the reaction to proceed. When substituted for a thiomethyl group, no reaction takes place. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00311-5

文献信息

• [EN] 2-PYRIDYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS<br/>[FR] INHIBITEURS DE TYROSINE KINASE DE LA RATE (SYK) CONTENANT UN 2-PYRIDYL CARBOXAMIDE
  申请人：MERCK SHARP & DOHME

  公开号：WO2013052394A1

  公开（公告）日：2013-04-11

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了一些含有2-吡啶甲酰胺的化合物，其化学式为(I)或药用可接受的盐，其中A和B按本发明定义。本发明还提供了包含这些化合物的药物组合物，以及使用这些化合物来治疗由脾酪氨酸激酶（Syk）介导的疾病或状况的方法。
• NITROXOLINE PRODRUG AND USE THEREOF
  申请人：Jiangsu Yahong Meditech Co., Ltd.

  公开号：US20210363165A1

  公开（公告）日：2021-11-25

  Provided are a nitroxoline prodrug and a use thereof. Specifically, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a composition containing the compound, and a use thereof in the preparation of anti-infective and antitumor drugs, and definitions of groups in formula (I) are as stated in the specification. The compound represented by formula (I) has better pharmacokinetic parameters such as solubility, blood medicine concentration, or half-life period than nitroxoline. The compound represented by formula (I) can reduce the frequency of drug administration, and has potential for application in other fields other than the field of urinary tracts.

  提供了一种硝基喹啉前药及其用途。具体提供了一种由式（I）表示的化合物或其药学上可接受的盐，其制备方法，含有该化合物的组合物，以及在制备抗感染和抗肿瘤药物中的用途，式（I）中的基团定义如规范中所述。由式（I）表示的化合物具有比硝基喹啉更好的药代动力学参数，如溶解度、血药浓度或半衰期。由式（I）表示的化合物可以减少药物给药频率，并且在泌尿道领域之外的其他领域具有应用潜力。
• [EN] DITERPENOID COMPOUNDS THAT ACT ON PROTEIN KINASE C (PKC)<br/>[FR] COMPOSÉS DITERPÉNOÏDES AGISSANT SUR LA PROTÉINE KINASE C (PKC)
  申请人：K GEN INC

  公开号：WO2021062030A1

  公开（公告）日：2021-04-01

  This present disclosure relates to protein kinase C (PKC) modulating compounds, methods of treating a subject with cancer using the compounds, and combination treatments with a second therapeutic agent.

  本公开涉及蛋白激酶C（PKC）调节化合物，使用这些化合物治疗癌症患者的方法，以及与第二治疗剂联合治疗的方法。
• [EN] KCNT1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE KCNT1 ET PROCÉDÉS D'UTILISATION
  申请人：PRAXIS PREC MEDICINES INC

  公开号：WO2020227101A1

  公开（公告）日：2020-11-12

  The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.

  本发明部分涉及用于预防和/或治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因（例如KCNT1）中的功能增强突变的化合物和组合物。本文还提供了治疗神经系统疾病或紊乱、与过度神经元兴奋性有关的疾病或病况，以及基因如KCNT1中的功能增强突变的方法。
• Tumour targeting prodrugs activated by metallo matrixproteinases
  申请人：——

  公开号：US20040248765A1

  公开（公告）日：2004-12-09

  A-(B) n —X   (I) A-(B) n -Q   (II) Structural Relationship of Example ( 8 ) to its Potential Metabolites 1 Numbers in Parentheses denote examples in the specification A compound is of general formula (I) wherein (A) is a moiety comprising one of more of a heterocylcic ring, a carbocyclic ring and a fused ring system, the ring or ring system being essential for a biological activity of the compound by action at a nucleic acid or protein target (B) is a bivalent spacer molecule attached directly to the ring system n is an integer 0 or 1 and (X) is a monovalent moiety containing a amide bond that is cleavable by the action of a matrix metalloproteinase enzyme such as to produce a compound of formula (II) wherein the efficacy of the biological activity of the compound of formula (II) is increased over that of the compound of formula (I).

  化合物的结构关系示例（8）与其潜在代谢产物的关系 1. 括号中的数字表示规范中的示例 化合物具有通式（I），其中（A）是包含杂环环、碳环环和融合环系统中的一个或多个的基团，该环或环系统通过作用于核酸或蛋白靶标而对化合物的生物活性至关重要；（B）是直接连接到环系统的二价间隔分子；n是整数0或1；（X）是含有可被基质金属蛋白酶酶作用而可裂解的酰胺键的一价基团，从而产生通式（II）的化合物，其中通式（II）的化合物的生物活性效力比通式（I）的化合物增加。